Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07709858
Recruiting Observational

CHATEAU Registry: Clinical Outcomes After Transcatheter Aortic Valve Replacement

NCT07709858 · tracked via the Priya Life Science South Korea tracker
Sponsor
Eunpyeong St. Mary's Hospital
Phase
Observational
Started
2021-01-01
Last updated
2026-07-17

Condition(s) studied

Aortic Valve StenosisTranscatheter Aortic Valve Replacement (TAVR)

Investigational drug(s) / intervention(s)

Transcatheter Aortic Valve Replacement

Transcatheter Aortic Valve Replacement: Transcatheter aortic valve replacement (TAVR) performed according to routine clinical practice using commercially available transcatheter heart valves and standard procedural techniques at participating centers.

Study summary

This study is a multicenter, retrospective registry study using the CHATEAU Registry. The study will evaluate patients who underwent transcatheter aortic valve replacement between January 2021 and December 2025. The purpose of the study is to assess clinical outcomes and valve performance after TAVR in real-world practice, with a focus on procedural strategies, valve-related factors, and long-term outcomes. Patient clinical information, imaging findings, procedural data, echocardiographic results, and follow-up outcomes will be collected from existing medical records. No additional intervention, treatment, or study-specific visit will be performed.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (≥18 years of age). * Patients who underwent transcatheter aortic valve replacement (TAVR) for severe native aortic valve disease at participating centers. * TAVR performed between January 1, 2021 and December 31, 2025. * Availability of baseline procedural and follow-up clinical data in the institutional registry or medical records. Exclusion Criteria: * Patients with insufficient clinical or procedural data for outcome assessment.

Primary outcome measure(s)

  • All-Cause Mortality — From the index TAVR procedure through December 31, 2027 (up to approximately 6 years)
    Death from any cause occurring after transcatheter aortic valve replacement (TAVR) during follow-up.

Trial sites (1)

FacilityCityRegionStatus
The Catholic University of Korea, Eunpyeong St. Mary's Hospital Seoul South Korea Recruiting

More Eunpyeong St. Mary's Hospital trials in South Korea

The Effect of Two Prokinetics in Patients With Functional Dyspepsia Active, not recruiting
Impact of Aortic Annulus Calcification on Long-Term Outcomes Following Transcatheter Aortic Valve Replacement: SAINT-TAVR Calcium Registry Recruiting

Other trials for the same condition

Korea VHD Echo Study: Surveillance of Aortic, Mitral & Tricuspid Patients - Insights From Real-world Practice Starting soon
Lipoprotein(a) and Progression of Aortic Stenosis Active, not recruiting
ASAN Medical Center Aortic Valve Replacement Registry Active, not recruiting
Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR) Starting soon
Evaluation of Effectiveness and Safety of Aortic Valve Replacement in Routine Clinical Practice Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07709858 on ClinicalTrials.gov ↗ ← All trials in South Korea